Archive for the ‘Stargardt disease’ Category
You wouldn’t think that being called an “orphan” is a good thing. But for developers of treatments for rare diseases — including inherited retinal conditions — “orphan” status provides valuable benefits, such as tax incentives, access to special research grants and assistance with clinical trial design. The orphan designation also gives seven years of market exclusivity to the developer of a treatment.
Found in Translation: Advancing Treatments Into Human Studies
I am always excited when a new research paper comes across my desk reporting on an emerging treatment that has saved or restored vision in an animal or cell-based model of retinal disease. The advancement provides meaningful hope for a therapy that can benefit people. But it raises a big question for the Foundation Fighting Blindness: What will it take to move the treatment into and through human studies?
Read more
Top 12 Research Advancements of 2012
At the Foundation Fighting Blindness, we are always looking forward. Our scientists are continually focused on achieving the next sight-saving breakthrough, and our donors and volunteers are always looking for new opportunities to raise more money to drive the research.
But for a moment, as we put the wraps on 2012, it is very inspiring to look back on the past year and reflect on the many exciting advancements that have been made in our quest for treatments and cures.
Read more
This week, the Foundation Fighting Blindness has much to be thankful for – its members, the tireless efforts of researchers and, of course, the readers of this blog, many of whom share their interest in our work via social media. But our biggest “thank you” goes to those who are directly affected by retinal diseases and do all they can to help FFB raise funds for research.








